{
  "pmcid": "3197816",
  "sha256": "d55e8f328c910a0cb2d30e2d71f207d28f676718f5f2d0b6c5aef180e1fd0f8c",
  "timestamp_utc": "2025-11-09T15:51:44.944833+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.81295336787565,
    "reading_ease": 36.812267835791175,
    "word_count": 386
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Effect of Lipid Modification on Peripheral Arterial Disease after Endovascular Intervention Trial (ELIMIT), which is a randomized trial"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "ongoing Effect of Lipid Modification on Peripheral Arterial Disease after Endovascular Intervention Trial (ELIMIT), which is a randomized trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients with PAD on ASA therapy at baseline were included from the ongoing Effect of Lipid Modification on Peripheral Arterial Disease after Endovascular Intervention Trial (ELIMIT)"
      },
      "Intervention": {
        "score": 2,
        "evidence": "testing whether combination treatment with ezetimibe, niacin, and a statin will halt/regress atherosclerosis compared to statin monotherapy"
      },
      "Objective": {
        "score": 1,
        "evidence": "Objective: To determine the prevalence of poor response to aspirin (ASA) therapy over 12-month follow-up in patients with lower extremity peripheral arterial disease (PAD), and to compare the classification agreement among different ASA response assays."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Main Outcome Measures: Patients who had baseline platelet testing and repeat testing at 6-month or 12-month follow-up were included."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Of 102 patients randomized in ELIMIT, 80 patients satisfied inclusion criteria."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "80 patients satisfied inclusion criteria."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "5% of subjects (4/80) were Persistent PRs by AA aggregation, compared to 27.5% (22/80) of subjects by ADP aggregation, and 9.9% (7/71) of patients by PFA-100 Epi. Regarding the agreement of the assays, only AA aggregation and PFA-100 Epi agreed significantly (K=0.3223; 95% CI 0.15â€“0.493, P=0.0001)"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}